Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian or Peritoneal Cancer
Status:
Terminated
Trial end date:
2018-05-08
Target enrollment:
Participant gender:
Summary
This 2-part, Phase 1/2 study will test investigational cancer drugs known as CRS-207,
epacadostat (IDO), and pembrolizumab (pembro). The purpose of this study is to find out how
safe it is to give the investigational drugs to women with platinum-resistant ovarian,
fallopian tube, or peritoneal cancer and if it helps patients with these types of cancer live
longer or can help shrink or slow the growth of cancer.